Article
Cell Biology
Sundy N. Y. Yang, Belinda Maher, Chunxiao Wang, Kylie M. Wagstaff, Johanna E. Fraser, David A. Jans
Summary: This study identifies two drugs that can inhibit the replication of dengue virus and other flaviviruses by directly binding to a viral protein.
Article
Virology
Vimal K. Maurya, Swatantra Kumar, Saniya Ansari, Amod K. Sachan, Umashankar Singh, Janusz T. Paweska, Ahmed S. Abdel-Moneim, Shailendra K. Saxena
Summary: This study aims to examine the antiviral activity of natural compounds against Japanese encephalitis virus (JEV) infection. The results show that curcumin provides the highest protection against JEV infection, while other natural compounds also have some protective effects but with lower efficacy compared to curcumin.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Microbiology
Marta Celegato, Mattia Sturlese, Vivian Vasconcelos Costa, Marta Trevisan, Angelica SamerLallo Dias, Ingredy Beatriz Souza Passos, Celso Martins Queiroz-Junior, Lorenzo Messa, Annagiulia Favaro, Stefano Moro, Mauro Martins Teixeira, Arianna Loregian, Beatrice Mercorelli
Summary: This study identifies two small molecules with pan-flavivirus antiviral potential through virtual screening of over 1 million compounds. The molecules inhibit the replication of dengue virus, Zika virus, and West Nile virus, and show efficacy in a mouse model of dengue.
Review
Immunology
Kangchen Li, Qianting Ji, Shibo Jiang, Naru Zhang
Summary: This review discusses the pathogenesis of ZIKV infection and summarizes the progress in the development of therapeutics against ZIKV infection, providing guidance for the development of effective therapeutics.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Immunology
Olivier Tshiani Mbaya, Philippe Mukumbayi, Sabue Mulangu
Summary: The unprecedented West Africa Ebola outbreak from 2013-2016 accelerated the development of medical countermeasures against Ebola virus disease. In the recent second-largest Ebola outbreak in the Democratic Republic of the Congo, two IPs, REGN-EB3 and mAb114, showed efficacy compared to the control arm ZMapp in an RCT. The FDA approved both medications, marking a significant advancement in EVD therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Ryan J. Malonis, James T. Earnest, Arthur S. Kim, Matthew Angeliadis, Frederick W. Holtsberg, M. Javad Aman, Rohit K. Jangra, Kartik Chandran, Johanna P. Daily, Michael S. Diamond, Margaret Kielian, Jonathan R. Lai
Summary: This study isolated and characterized MAYV-reactive human monoclonal antibodies from a CHIKV-convalescent donor, revealing five mAbs that can potently neutralize multiple alphaviruses. Two of these broadly neutralizing mAbs provided protection against musculoskeletal disease induced by CHIKV and MAYV in mice.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Virology
Du Yu, Yundi Zhao, Junhui Pan, Xingmiao Yang, Zhenjie Liang, Shengda Xie, Ruibing Cao
Summary: C19orf66, a novel interferon-stimulated gene product, can inhibit JEV replication by targeting -1 PRF and the NS3 protein. The study suggests that C19orf66 may possess at least two different mechanisms of antagonizing JEV infection.
Article
Biochemistry & Molecular Biology
Sanjay Kumar, Sherif A. El-Kafrawy, Shiv Bharadwaj, S. S. Maitra, Thamir A. Alandijany, Arwa A. Faizo, Aiah M. Khateb, Vivek Dhar Dwivedi, Esam Azhar
Summary: This study utilized molecular simulations to explore potential therapeutic compounds against the Zika virus from the Azadirachta indica plant. Four common bioflavonoids were identified as promising inhibitors with substantial binding energy and interactions with essential residues of the Zika virus proteins. Molecular dynamics simulations confirmed the stability of the docked poses, and the calculated binding free energy further supported the predicted complex stability. These compounds are recommended for further experimental assessment.
Article
Pharmacology & Pharmacy
Ludek Eyer, Katherine Seley-Radtke, Daniel Ruzek
Summary: Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. Currently, there is no specific therapy for TBE patients, but there are ongoing efforts to develop small molecules and monoclonal antibodies that can interfere with the TBE virus life cycle and potentially be used for post-exposure prophylaxis or early therapy. This review summarizes the latest directions and experimental approaches for combating TBE in humans.
ANTIVIRAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Emanuele Andreano, Ida Paciello, Giulia Piccini, Noemi Manganaro, Piero Pileri, Inesa Hyseni, Margherita Leonardi, Elisa Pantano, Valentina Abbiento, Linda Benincasa, Ginevra Giglioli, Concetta De Santi, Massimiliano Fabbiani, Ilaria Rancan, Mario Tumbarello, Francesca Montagnani, Claudia Sala, Emanuele Montomoli, Rino Rappuoli
Summary: Research suggests that individuals who have been infected or vaccinated for the first time will produce antibodies with increased potency and breadth, allowing for better control of emerging SARS-CoV-2 variants.
Article
Virology
Toshitada Takemori, Akiko Sugimoto-Ishige, Hironori Nishitsuji, Yushi Futamura, Michishige Harada, Tomomi Kimura-Someya, Takehisa Matsumoto, Teruki Honma, Miho Tanaka, Masami Yaguchi, Kyoichi Isono, Haruhiko Koseki, Hiroyuki Osada, Daiki Miki, Takashi Saito, Takashi Tanaka, Takehiro Fukami, Toshio Goto, Mikako Shirouzu, Kunitada Shimotohno, Kazuaki Chayama
Summary: Entry inhibitors are being developed to enhance the treatment of HBV patients with oral nucleoside/nucleotide analogues (NA). Therapeutic MAbs with neutralizing activity against HBs antigens have been developed to amplify the effectiveness of NA therapy. Targeting NTCP can provide an effective treatment option for patients with chronic hepatitis B, regardless of viral genotype, mutations, and the presence of subviral particles.
JOURNAL OF VIROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Alessandro Rocca, Carlotta Biagi, Sara Scarpini, Arianna Dondi, Silvia Vandini, Luca Pierantoni, Marcello Lanari
Summary: Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in children worldwide, and while only symptomatic treatment is available, passive immune prevention methods are being developed for all infants. The high cost of passive immunoprophylaxis limits its prescription to high-risk children, though most hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Virology
Liuxing Qin, Tingting Rao, Xiangmin Li, Huanchun Chen, Ping Qian
Summary: This study identified DnaJA2 as a crucial host factor in JEV infection and suggested it as a potential target for antiviral therapies against JEV.
Article
Microbiology
Abdul Wahaab, Ke Liu, Muddassar Hameed, Muhammad Naveed Anwar, Lei Kang, Chenxi Li, Xiaochun Ma, Abdul Wajid, Yi Yang, Umair Hassan Khan, Jianchao Wei, Beibei Li, Donghua Shao, Yafeng Qiu, Zhiyong Ma
Summary: This study investigated the proteolytic processing of polyprotein mediated by NS2B-NS3 protease in Japanese encephalitis virus (JEV) infection using eukaryotic and prokaryotic cell models. The results showed that cleavage efficiency of cleavage sites by host cell proteases varied, with certain sites being specifically cleaved by JEV NS2B-NS3 protease. These findings provide insight into JEV replication and pathogenesis.
Article
Biochemistry & Molecular Biology
Aiping Wang, Jinran Du, Hua Feng, Jingming Zhou, Yumei Chen, Yankai Liu, Min Jiang, Rui Jia, Yuanyuan Tian, Gaiping Zhang
Summary: This study successfully cloned the BTV1 VP2 gene and expressed the protein in insect cells, leading to the production of effective vaccines. Three anti-BTV1 VP2 monoclonal antibodies were generated, and a novel B-cell epitope on the VP2 protein was identified, laying a foundation for the development of diagnostic and prophylactic methods for bluetongue disease.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
